# Case Report: Whole-genome sequencing of urothelial carcinoma in an adult patient with CLOVES syndrome reveals a lack of PIK3CA mutation and a genomic landscape consistent with urothelial carcinoma

## TL;DR

Whole-genome sequencing of a urothelial carcinoma in a patient with CLOVES syndrome found no PIK3CA mutations, indicating the cancer was unrelated to the syndrome.

## Contribution

This case report provides genomic insights into urothelial carcinoma in a CLOVES syndrome patient, showing no PIK3CA mutations.

## Key findings

- Somatic alterations in the tumor were consistent with typical urothelial carcinoma features.
- No somatic PIK3CA mutations were detected in the tumor tissue.
- Homozygous deletions of CDKN2A and CDKN2B were observed.

## Abstract

Congenital lipomatous overgrowth, vascular epidermal nevi, and skeletal abnormalities (CLOVES) syndrome is a rare genetic disorder caused by somatic activating mutations in the PIK3CA gene that arise during embryonic development. Mutations in the PI3K–AKT–mTOR pathway have been linked to various benign overgrowth disorders, including syndromes within the PIK3CA-related overgrowth spectrum. Somatic PIK3CA mutations also occur frequently across many cancer types; however, evidence linking CLOVES syndrome to increased cancer risk is not conclusive. Here, we describe a whole-genome sequencing (WGS) study of a primary pT3 high-grade urothelial carcinoma in a 62-year-old male patient diagnosed with CLOVES syndrome. A left laparoscopic nephroureterectomy was completed. Tumour tissue and a matched blood sample were collected for whole-genome sequencing, and somatic variant detection was performed. The somatic alterations were consistent with previous reports of urothelial carcinoma, including homozygous deletions of CDKN2A and CDKN2B. In this case, we could not detect somatic PIK3CA alterations in this patient’s urothelial carcinoma and suggest that it is unrelated to CLOVES syndrome.